SCHEMBL4067308

SCHEMBL4067308

CC(O)(CC[C@H](C[C@@H](O)[CH]Cc1ccc2ccccc2c1)C(N)=O)C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FCER2 P06734 1/20 0.38
MMP9 P14780 1/20 0.38
REN P00797 2/20 0.37
SLC13A5 Q86YT5 1/20 0.37
CYP1A2 P05177 1/20 0.36
VNN1 O95497 1/20 0.35
CCR1 P32246 4/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
PDPK1 O15530 1/20 0.34
EPHX1 P07099 1/20 0.34
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34
F7 P08709 1/20 0.34
CHRM2 P08172 1/20 0.34
CCR5 P51681 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7687929 0.92 CCR1 (0.42) FCER2MMP9RENSLC13A5CYP1A2
SCHEMBL4068329 0.90 FCER2 (0.43) FCER2MMP9RENVNN1CCR1
SCHEMBL2675071 0.87 CCR1 (0.40) CCR1EPHX1CHRM2CCR5
SCHEMBL2677146 0.84 RIPK1 (0.33) CCR1CHRM2CCR5
SCHEMBL2675741 0.83 CCR1 (0.44) VNN1CCR1CHRM2CCR5
SCHEMBL3825742 0.83 CCR1 (0.44) VNN1CCR1CHRM2CCR5
SCHEMBL2676714 0.83 HTR3E (0.35) CCR1CHRM2CCR5
SCHEMBL2675799 0.81 REN (0.35) RENVNN1CCR1
SCHEMBL4389912 0.81 CCR1 (0.35) CCR1CHRM2CCR5
SCHEMBL2676320 0.79 CCR1 (0.43) VNN1CCR1CHRM2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966443-B1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER (US) 2009-01-28 EP disclosed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US disclosed